Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Likely To Lose Cost-Watchdog Status By 2013

Executive Summary

The U.K.'s National Institute for Clinical Excellence (NICE) will likely no longer have any role in drug cost-effectiveness decisions after 2013, according to officials.

You may also be interested in...



Could Japan's Chuikyo Embrace NICE Model As New Chairman Takes Reign?

The new chairman of Japan's Central Social Medical Insurance Council (Chuikyo), the committee that determines drug pricing for Japan's National Health Insurance, will consider the possibility of linking drug pricing to health technology assessments, similar to the UK's National Institute for Health and Clinical Excellence

NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future

A lack of good clinical trial data on the use of Sprycel, high-dose Glivec and Tasigna in imatinib-resistant chronic myeloid leukemia patients leads to rejection by NICE in a draft guidance.

NICE Launches Clinical Guidelines Website In Anticipation Of New Role

The U.K.’s National Institute for Health and Clinical Excellence launched a new section within its website dedicated to providing health care providers with evidence-based guidelines. The addition comes in anticipation of the proposed change in NICE’s role, which would emphasize promoting best practices rather than determining the cost-effectiveness of drugs.

Related Content

Topics

UsernamePublicRestriction

Register

LL029263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel